89bio to Participate in the 7th Annual Evercore HealthCONx Conference
89bio (Nasdaq: ETNB) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 8:20 AM ET, along with one-on-one investor meetings. The event will be accessible via webcast through 89bio's investor website section, with replay available for approximately 30 days post-conference. 89bio is a clinical-stage biopharmaceutical company developing innovative therapies for liver and cardiometabolic diseases.
89bio (Nasdaq: ETNB) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. Il management dell'azienda parteciperà a una chiacchierata informale martedì 3 dicembre 2024, alle 8:20 AM ET, insieme a incontri one-to-one con gli investitori. L'evento sarà accessibile tramite webcast attraverso la sezione dedicata agli investitori del sito web di 89bio, con la possibilità di rivederlo per circa 30 giorni dopo la conferenza. 89bio è un'azienda biofarmaceutica in fase clinica che sviluppa terapie innovative per le malattie epatiche e cardiometaboliche.
89bio (Nasdaq: ETNB) ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx. La dirección de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a las 8:20 AM ET, junto con reuniones uno a uno con inversores. El evento será accesible a través de un webcast en la sección de inversores del sitio web de 89bio, con reproducción disponible durante aproximadamente 30 días después de la conferencia. 89bio es una empresa biofarmacéutica en etapa clínica que desarrolla terapias innovadoras para enfermedades hepáticas y cardiometabólicas.
89bio (Nasdaq: ETNB)는 제7회 연례 Evercore HealthCONx 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 12월 3일 화요일 오전 8시 20분 ET에 간담회에 참석하며, 투자자와의 일대일 미팅도 진행할 예정입니다. 이 이벤트는 89bio의 투자자 웹사이트 섹션을 통해 웹캐스트로 접근 가능하며, 컨퍼런스 종료 후 약 30일 동안 재생할 수 있습니다. 89bio는 간 및 심대사 질환에 대한 혁신적인 치료제를 개발하는 임상 단계의 생물약품 회사입니다.
89bio (Nasdaq: ETNB) a annoncé sa participation à la 7ème Conférence Annuelle Evercore HealthCONx. La direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024, à 8h20 ET, avec des réunions individuelles avec des investisseurs. L'événement sera accessible par webcast via la section dédiée aux investisseurs du site web de 89bio, avec une rediffusion disponible pendant environ 30 jours après la conférence. 89bio est une entreprise biopharmaceutique en phase clinique qui développe des thérapies innovantes pour les maladies hépatiques et cardiométaboliques.
89bio (Nasdaq: ETNB) hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx-Konferenz bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 8:20 Uhr ET an einem informellen Gespräch teilnehmen, zusammen mit Einzelgesprächen mit Investoren. Die Veranstaltung wird über einen Webcast über den Investorenbereich der 89bio-Website zugänglich sein, mit einer Wiedergabe, die etwa 30 Tage nach der Konferenz verfügbar ist. 89bio ist ein biopharmazeutisches Unternehmen in klinischer Phase, das innovative Therapien für Leber- und kardiometabolische Erkrankungen entwickelt.
- None.
- None.
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.
The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
When is 89bio (ETNB) presenting at the Evercore HealthCONx Conference 2024?
How long will the replay of 89bio's (ETNB) Evercore Conference presentation be available?
What type of diseases does 89bio (ETNB) focus on treating?
Where can investors access 89bio's (ETNB) Evercore Conference presentation?
